- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Banking and Institutional Finance
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Emerging Companies and Venture Capital
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Global Human Capital and Compliance
- Investment Funds and Asset Management
- Mergers and Acquisitions (M&A)
- Middle East and Islamic Finance and Investment
- Private Credit & Special Situations
- Private Equity
- Public Companies
- Real Estate
- Structured Finance and Securitization
- Tax
- Technology Transactions
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Government Contracts
- Healthcare
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Antitrust
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Construction and Engineering Disputes
- Corporate and Securities Litigation
- E-Discovery
- Intellectual Property
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
- back
- Industries / Issues
- Automotive, Transportation and Mobility
- Energy Transition
- Energy
- Financial Services
- Food and Beverage
- Higher Education
- Life Sciences and Healthcare
- Technology
- #MeToo
- Artificial Intelligence and Machine Learning
- Buy American
- Crisis Management
- Doing Business in Latin America
- Environmental Agenda
- Environmental, Social and Governance (ESG)
- Focus on Women's Health
- Russia/Ukraine
- Special Purpose Acquisition Companies (SPACs)
- Careers
- News & Insights
- About
- Languages
David J. Farber
News 13 results
In the News · Source: Verywell Health
July 14, 2023
David Farber discusses the FDA recently granting full approval to Leqembi, a drug to treat mild Alzheimer’s disease
Recognition
June 8, 2023
King & Spalding Earns Top-Tier Rankings in Legal 500 United States 2023 Guide
In the News · Source: Drug Channels
December 12, 2022
David Farber, Preeya Pinto, John Shakow, Eva Temkin and Christine Carletta’s client alert is referenced in a profile on the Inflation Reduction Act of 2022
Recognition
June 8, 2022
Legal 500 United States 2022 Recognizes King & Spalding Practices and Lawyers Among the Top in the Nation
In the News · Source: Verywell Health
In the News · Source: Verywell Health
November 18, 2021
David Farber comments on the new infrastructure law and the provisions that are included to improve public health
Recognition
June 10, 2021
Legal 500 United States 2021 Ranks King & Spalding Practices Among the Top in the Nation
In the News · Source: NPR
April 9, 2021
David Farber explains why a vaccinated person is not required to share that information with everyone who asks
In the News · Source: Alliance for Aging Research
March 12, 2021
David Farber explains how international reference pricing would impact older adults and their access to prescription drugs
In the News · Source: Global Legal Chronicle
Cases & Deals
December 31, 2020
King & Spalding Advises on Landmark Medicare Reform Bills BENES Act and PAID Act, Both Passed By Congress
In the News · Source: The Punxsutawney Spirit
December 16, 2020
David Farber and Christine Carletta file an amicus brief on behalf of Alliance for Aging Research seeking to halt implementation of CMS’ MFN Rule